Helix BioPharma Corp. to divest remaining ownership of Polish subsidiary

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has entered into a non-binding term sheet to divest the remaining shares it holds in its Polish subsidiary (the “Divestment”), Helix Immuno-Oncology S.A. (“HIO”), representing approximately 51% of the issued and outstanding shares of HIO prior to the HIO Private Placement.

20200626 – HBP Press Release – HIO divestiture